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Resumo 
 
 
Recentemente, as nanopartículas de ouro têm sido estudadas para diferentes aplicações 
biomédicas e, também, como promissores sistemas de libertação de fármacos em terapias 
anticancerígenas. 
Neste trabalho, foram sintetizados nanopartículas de ouro e conjugadas com doxorrubicina e um 
inibidor de tirosina quinase, varlitinib. A doxorubicina é um fármaco utilizado em quimioterapia 
classificado como uma antraciclina. Este fármaco tem sido aplicado em diferentes carcinomas, 
tais como o cancro do pulmão, do pâncreas, da bexiga e da mama. Os  inibidores de tirosina-
quinase são uma classe de agentes quimioterapêuticos que inibem, ou bloqueiam, a enzima 
tirosina-quinase. As tirosina-quinases são enzimas responsáveis pela activação de muitas 
proteínas de cascatas de transdução de sinal. 
O principal objectivo deste projecto foi o de conjugar ambos os fármacos anti-cancerígenos em 
nanopartículas de ouro funcionalizadas, com o objetivo de obter uma resposta sinérgica. 
Ambos os fármacos anti-cancerígenos foram conjugados com sucesso às nanopartículas, através 
de um processo sequencial de peguilação (funcionalização de AuNPs com poli (etileno) glicol 
[PEG]), ativação química do PEG e conjugação dos fármacos. 
As nanopartículas de ouro peguiladas (PEGAuNPs) e conjugadas foram sintetizadas e 
caracterizadas quanto ao seu tamanho (Espalhamento de Luz Dinâmico, Espectroscopia de 
Absorção), morfologia (Microscopia Eletrônica de Transmissão), estabilidade em solução 
(Espalhamento de Luz Electroforético) e estrutura química (Fourier Transform Infrared 
Spectroscopy). 
As nanopartículas conjugadas exibem uma libertação controlada dos fármacos anti-cancerígenos, 
durante 72 horas. Os perfis de libertação foram obtidos por comparação da análise fluorimétrica 
dos fármacos na presença e ausência das nanopartículas em solução. 
Em conclusão, os nanosistemas desenvolvidos podem ser uma alternativa promissora para a 
terapia do cancro. 
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Abstract 
 
 
 
Recently, gold nanoparticles have been studied for different biomedical applications and, also, 
as promising delivery systems for cancer treatments.  
In this work, gold nanoparticles were synthesized and conjugated with doxorubicin and a 
tyrosine kinase inhibitor, varlitinib. Doxorubicin is a chemotherapy drug classified as an 
anthracycline. This anticancer drug has been used in different carcinomas such as non-small cell 
lung cancer, pancreatic cancer, bladder cancer and breast cancer. Tyrosine-kinase inhibitors are 
a class of chemotherapy agents that inhibit, or block, the enzyme tyrosine kinase. Tyrosine 
kinases are enzymes responsible for the activation of many proteins by signal transduction 
cascades. 
The main goal of this project was to conjugate both anticancer drugs to functionalized gold 
nanoparticles, aiming to reach a synergic.  
Both anticancer drugs were successfully conjugated to the nanoparticles, through a sequential 
process of pegylation (functionalization of AuNPs with poly-(ethylene) glycol [PEG]), PEG 
chemical activation and drug conjugation. 
Pegylated gold nanoparticles with drug conjugation were synthesized and characterized 
regarding their size (Dynamic Light Scattering, Absorption Spectroscopy), morphology 
(Transmission Electron Microscopy), stability in solution (Laser Doppler Velocimetry) and 
chemical structure (Fourier Transform Infrared Spectroscopy).  
The conjugated nanoparticles displayed a controlled release of the anticancer drugs, through a 
72-hour timeline. The release profiles were obtained by comparing the fluorimetric analysis of 
conjugated nanoparticles in solution with the drugs alone in suspension. 
In conclusion, the nanosystems developed can be a promising alternative for cancer therapy.   
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1.1. Classic cancer therapies and its challenges 
 
With an ever increasingly older population, cancer casts a very large shadow over the 
world, particularly in developing countries. Whether due to environmental factors or cancer-
causing behaviors, such as smoking, the death toll associated with this once considered incurable 
disease continues to grow. According to the 2008 GLOBOCAN project, it is estimated that about 
12.7 million cancer cases and 7.6 million cancer deaths have occurred in 2008. Of these, 56% of 
the cases and 64% of the deaths occurred in the economically developing world [1]. 
The sheer volume of this numbers, calls for a constant improvement in both diagnostic 
and therapeutic approaches. Currently, surgery, chemo and radiotherapy are the leading 
therapeutic approaches, all of them possessing intrinsic and undesirable side effects. Although 
surgery and radiotherapy are considered local therapies, chemotherapy acts systemically through 
the bloodstream. This posts a major issue for such approaches, mostly due to the high toxicity of 
the antitumoral drugs, their short life-time in the human body and lack of specificity to the 
tumor site. Many drugs are merely removed in their first blood circulation through the kidney 
and the liver, breaking apart before reaching their targets. Another problem which is 
encountered in conventional anticancer drugs is their low solubility, requiring a large amount of 
drug to be used in order to be effective, which, in most cases exceeds their dose-limiting 
toxicity, as previously referred [2–6]. 
Considering the sum of these facts, it is quite obvious that a novel, more targeted and 
less harmful approach, must be established. For both diagnostic and therapeutic approaches, 
nanomedicine may have come up with a solution: nanoparticles. In this study a specific category 
of nanoparticles will be highlighted, gold nanoparticles, as they show great promise and 
potential in a wide array of clinical applications. 
 
.  
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1.2. Nanoparticles 
 
Nanoparticles (NPs) are usually smaller than several hundred nanometers in size, 
comparable to large biological molecules such as enzymes, receptors, and antibodies. With size 
ranging about one hundred to ten thousand times smaller than human cells, these nanoparticles 
are able to interact with biomolecules both on the surface of and inside the cells, which may 
revolutionize cancer diagnosis and treatment. Other features associated with these particles are 
their unique physicochemical properties such as: small size, larger surface area, stability, varied 
composition, biocompatibility and biodegradability [7–11]. Through distinct synthesis processes, 
different types of nanoparticles may be obtained, from dendrimers to liposomes, nanospheres to 
nanotubes or nanocapsules. Each of these structures has its advantages and disadvantages, and 
one must take into consideration its features when selecting the nanocarrier for the targeted 
approach. 
Recently, nanoparticles of several types of materials (such as lipids, metals or other 
compounds) have been studied and regarded as a great alternative for the conventional cancer 
therapies, or even at a diagnosis level through new bioimaging techniques. Briefly, Table 1 
highlights some of the materials used in the preparation of nanocarriers. 
  
Table 1- Nanosystems in drug delivery applications and materials used in its fabrication. 
Nanosystem Materials References 
Dendrimers Poly(amidoamine); [12] 
Inorganic Nanoparticles 
 
Polymer-based Nanoparticles 
 
Lipossomes 
Gold Nanoparticles (AuNPs); carbon 
nanotubes; silica nanoparticles 
Poly(ciano)acrylates; 
Polyethyleinemine; Polysaccharides; 
Phospholipids; 
[13–15] 
 
[16], [17] 
 
[18–20] 
 
The main aims of these strategies are to overcome non-cellular and cellular mechanisms 
of resistance and to boost the selectivity of the drugs towards tumor cells, thus reducing their 
toxicity regarding normal tissue cells. To deliver therapeutic agents to tumor cells, several 
problems must be addressed and solved. Firstly, drug resistance at the tumor level due to 
physiological barriers (non-cellular based mechanisms). Secondly, drug resistance at the cellular 
level (cellular mechanisms). Finally, the distribution, biotransformation and clearance of 
anticancer drugs in the system must be assessed. Several studies state that, using nanoparticles 
as drug delivery or simply as a bioimaging toll, all of these barriers may be overcome [3], [8], 
[21–23]. 
To bypass the inherent limitations of the classic cancer therapies, several drug delivery 
systems have been a part of the edge in scientific research. It is crucial to improve the retention 
and release of therapeutic and diagnostic agents to overcome the refereed limitations [14], [15]. 
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 Nanoparticles are considered the gold standard of drug delivery nanosystems, due to their 
aforementioned intrinsic characteristics. By encapsulating drugs in a nanoparticle, the drug’s 
bioavailability and bioaccumulation in the target site will improve, decreasing its toxicity. The 
fulfillment of these main goals allows maximizing therapeutic effects and minimizing side 
effects. These goals are achieved by drug encapsulation itself, but also by modifying NPs’ 
surface. The encapsulation of the drug minimizes its premature degradation after 
administration, since it allows protection and stabilization of the drug against environmental or 
biological factors. This drug increased stability promotes an enhancement in its bioavailability. 
Also, in order to increase the bioavailability of the drug, the functionalized NP allows 
overcoming the biological barriers that would lead to its elimination. The toxicity of the drug is 
also reduced since NPs allows the use of lower doses, since the delivery may be localized rather 
than systemic. Also a decrease in toxicity is due to the drug being less likely to act on healthy 
cells, since it is possible to guide the NPs to the diseased tissues, increasing accumulation in the 
target tissues, through the Enhanced Permeability and Retention (EPR) effect (Figure 1). 
The EPR effect is a unique phenomenon of solid tumors based on their anatomical and 
pathophysiological differences from healthy tissues. Since angiogenesis leads to high vascular 
density in solid tumors, large gaps exist between endothelial cells in tumor blood vessels, and 
tumor tissues show selective extravasation and retention of macromolecular drugs or even 
nanoparticles [22], [24]–[27]. This EPR effect served as a basis for development of several 
anticancer nanoparticle therapies. 
 
 Figure 1-Enhanced drug delivery to solid tumors using nanoparticles: (A) Passive targeted delivery. (B) 
Active targeted delivery [27]. 
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1.2.1 Gold Nanoparticles 
 
Gold nanoparticles (AuNPs) with controlled geometrical, optical, and surface chemical 
properties are the subject of intensive studies and applications in biology and medicine. 
Presently, there is a wide diversity of published examples which includes genomics and 
biosensorics, immunoassays and clinical chemistry, photothermolysis of cancer cells and tumors, 
targeted delivery of drugs and antigens, and optical bioimaging of cells and tissues with 
nanophotonic detection systems [8].  
There are several ways to synthesize AuNPs with most of them starting from commercial 
HAuCl4. Citrate reduction of Au
III to Au0 in water was introduced by Turkevitch et al. in 1951, a 
method that is still used nowadays to subsequently replace the citrate ligand of these AuNPs by 
appropriate ligands of biological interest [10], [28]. Recent modifications of the Turkevitch 
method have allowed better size distribution and size control within the 9–120 nm range [6], 
[29]. AuNPs can be stabilized by a large variety of stabilizers (ligands, surfactants, polymers, 
dendrimers or biomolecules), allowing for an even broader diversity of these particles. However, 
it has been established that the most robust AuNPs were developed by Giersig and Mulvaney 
through stabilization by thiolates using the strong Au–S bond between the soft acid Au and a soft 
thiolate base [30]. In figure 2, several different types of gold nanoparticles are represented. 
 
Figure 2-Various types of plasmon-resonant nanoparticles: 16 nm nanospheres (a); gold nanorods (b); 
gold bipyramids (c); gold nanorods (d); ‘‘nanorice’’ (gold-coated Fe2O3 nanorods) (e); SiO2/Au nanoshells 
(f) (the inset shows a hollow nanoshell); nanobowls with bottom cores (g); spiky SiO2/Au nanoshells (h) 
(the inset shows a gold nanostar); gold tetrahedra, octahedra, and cubooctahedra (i); gold nanocubes 
(j); silver nanocubes and gold–silver nanocages obtained from them (in the insets) (k); and gold 
nanocrescents (l)[8]. 
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A unique feature of this solution is its color oscillation, which is directly correlated with the 
size of the particles in suspension. This feature is a reflection of the Surface Plasmon Band, a 
physical property described as a broad absorption band in the visible region around 520 nm. 
Smaller particles provide a deep-red color, while increasingly larger ones lead to a shift the 
absorption peak to higher wavelengths, giving the solution a purple hue [5], [10]. 
Due to its unique characteristics, AuNPs may be applied to both diagnostics and therapy 
(Figure 3). Several studies describe these particles as a bioimaging tool and, historically, 
electron microscopy (mainly transmission electron microscopy [TEM]) has for a long time been 
the principal method to detect specific biological interactions with the help of colloidal gold 
particles in suspension (due to their high electron density)[8], [31]. Concerning its therapetuical 
applications, photothermal or photodynamic approaches are frequently found in clinical 
situations. Most recently, several research groups associate or conjugate drugs or genes to 
AuNPs, acting as a drug delivery agent [4], [5], [32].  
 
Figure 3- Generalized scheme for the biomedical application of gold nanoparticles (AuNPs). Along with 
basic applications in diagnostics and therapy [8]. 
 
 
As previously mentioned, there is an enhanced retention of the particles in tumor tissue, 
leading to an accumulation in such sites. Due to its small size, AuNPs are easily internalized by 
tumor cells, via lysosomes. Here, alterations in pH values lead to an increased release of 
therapeutic agents, when conjugated to the particles. Such reaction greatly decreases the 
necessary drug concentrations administered to the organism, reducing its side effects, but also 
increasing the treatment specificity and efficiency. Usually, to enhance the stability and 
bioavalability of the particles, a poly-(ethylene) glycol (PEG) coating is carried out. PEG coating 
not only stealths the nanoparticles from the body’s immune system but also facilitates the 
conjugation of several drugs, through the functionalization of the terminal site of the PEG 
molecule [5], [33].  
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Despite its innate potential for bioimaging, AuNPs have also been intensively studied as a 
therapeutic agent and have been developed as effective carriers for drug delivery because of 
their high tissue permeability, high colloidal stability, and small size. Several clinical trials 
applying this colloidal system exist, particularly for pancreatic, ovarian and breast cancer, 
melanoma and multiple myeloma [3–5], [11], [32], [34].  
There is a vast array of chemotherapeutical agents being conjugated to pegylated gold 
nanoparticles (PEGAuNPs), with promising results. Table 2 briefly resumes the current 
applications of these systems. 
Table 2- Antitumor substances conjugated with AuNPs [4], [8], [35], [36] 
Drugs Size Functionalization Cell lines 
Paclitaxel AuNPs, 26 nm PEG–SH as a linker 
MC-38; C57/BL6 mice 
implanted with B16/F10; 
melanoma cells 
Oxaliplatin AuNPs, 30 nm PEG–SH as a linker 
A549, HCT116, HCT15, 
HT29, RKO 
Tamoxifen AuNPs, 25 nm PEG–SH as a linker MDA-MB-231, MCF-7, HSC-3 
b-Lapachon AuNPs, 30 nm PEG–SH as a linker MCF-7 
Doxorubicin AuNPs, 12 nm Physical adsorption KB 
Cisplatin AuNPs, 5 nm PEG–SH as a linker 
OV-167, OVCAR-5, 
HUVEC, OSE 
Bortezomib AuNPs, 20 nm PEG–SH as a linker Du145 
Afatinib AuNPs, 20 nm PEG–SH as a linker S2-013, A549 
 
1.3. Doxorubicin and its role in cancer therapy 
 
Doxorubicin (DOX) is an antibiotic anthracycline, a class of drugs derived from Streptomyces 
bacterium Streptomyces peucetius. This class of drugs is perceived as the most effective 
anticancer treatment developed and is effective against a wide range of cancer phenotypes, 
especially when compared to other class of chemotherapeutic agents [37], [38]. Doxorubicin’s 
modus operandi consists of an inhibition of the synthesis of DNA by intercalating into the DNA 
strand, by interference in the activity of DNA topoisomerase II (TOP2). It is at the peak of its 
activity in cells undergoing rapid proliferation and are expressing high levels of TOP2 [39].  Other 
effects have been associated to this drug, such as cell apoptosis triggered by ceramide 
production, increased free radical production and even cell-cycle checkpoint arresting [39], [40]. 
Having so many distinct effects on cellular behavior, Doxorubicin has been extensively 
studied in several in vitro researches. A work developed by Zimmermman et al. claims that 
doxorubicin induced G2/M checkpoint arrest by elevating cyclin G2 (CycG2) expression and 
phospho-modification of proteins in the ataxia telangiectasia mutated signaling pathways [41]. 
Mandili et al. treated neuroblastoma cells with nanomolar doxorubicin, causing dose-dependent 
over-ubiquitination of a specific set of proteins, indicating that Doxorubicin may also exert its 
effect through protein damaging [42]. 
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Some in vivo studies have already been carried out, using doxorubicin in association with 
other compounds. For example, a study combining doxorubicin with adenoviral manganese 
superoxide dismutase (MnSOD) lead to a decrease in MB231 tumors and prolonged survival, in 
mice [43]. There is also a Phase III clinical trial in subjects with locally advanced unresectable or 
metastatic soft tissue sarcoma. 
 
Figure 4- Chemical structure of doxorubicin (Adriamycin)[38]. 
 
1.3.1 Gold Nanoparticles as Doxorubicin carriers 
 
Some research groups have already established systems with doxorubicin conjugated to gold 
nanoparticles, with variations regarding both the conjugation reaction and the final conjugate 
structure. The most common and efficient process, although, is through PEG functionalization 
with cross-linking reagents such as 1-ethyl-3-(3dimethylaminopropyl)-carbodiimide (EDC) and 
Sulfo-N-hydroxysulfosuccinimide (NHS). This reaction greatly increases the PEGAuNPs 
susceptibility to link with other compounds. Figure 5 briefly summarizes the standard 
conjugation reaction. 
 
Figure 5-Template for the usual conjugation reaction between PEGAuNPs and doxorubicin. 
PEG itself lacks reactivity towards biochemical agents, an advantage for the particles 
stability, but a drawback regarding its functionalization. Another pathway to ensure the drug’s 
conjugation to the particles it’s the functionalization of the drug itself, instead of the NPs. For 
example, through thiolation of DOX, a research group was able to successfully conjugate the 
drug to pegylated gold nanoparticles. One of the drawbacks of such approach might reside in the 
attenuation of the drug’s bioactivity by structural alterations [4]. Finally, another approach to 
ensure the functionalization of the AuNPs is via a direct ligand between the PEG chain and the 
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molecule of interest. Some of the chosen compounds for this task are hydrazine or folic acid [5], 
[21]. 
Some in vitro studies have been developed to access the potential of gold nanoparticles in 
conjugation with doxorubicin. According to Spadavecchia et al., due to its interaction with DNA 
chains, DOX-conjugated AuNPs may be considered a useful tool to detect, in a sensitive manner, 
DNA hybridisation events [44]. Another important characteristic of such conjugates has been 
reported by Aryal et al., claiming that this nanoparticles show a pH-responsive release of the 
antitumoral drug, a vital feature for these drug nanocarriers [21]. More recently, a work 
developed by Elbialy et al., concluded that, in presence of a suitable external magnetic field, 
the administration of DOX-conjugated gold nanoparticles presents the best therapeutic 
anticancer activity and lowest systemic toxicity when compared to that of free DOX [45]. 
 
1.4. Tyrosine-kinase inhibitors in chemotherapy 
 
Conventional chemotherapy, despite being directed toward certain macromolecules or 
enzymes, typically does not discriminate effectively between rapidly dividing normal cells (e.g., 
bone marrow and gastrointestinal tract) and tumor cells, leading to several undesired toxic side 
effects. Tumor responses from cytotoxic chemotherapy are usually unpredictable. To overcome 
this obstacle, targeted therapies interfering with molecular targets that have a role in tumor 
growth or progression emerged as a solution. These targets are usually located in tumor cells, 
although some (e.g. antiangiogenic agents) may target other cells such as endothelial cells. 
There are multiple types of targeted therapies available, including monoclonal antibodies, 
inhibitors of tyrosine kinases, and antisense inhibitors of growth factor receptors. Tyrosine kinase 
inhibitors (TKI) are effective in the targeted treatment of various malignancies via the 
competitive ATP inhibition at the catalytic binding site of tyrosine kinase. These compounds 
present several side effects on skin and hair such as folliculitis, paronychia, facial hair growth, 
facial erythema, and varying forms of frontal alopecia [46–48]. A resumed overview of some 
inhibitors being studied is displayed in table 3. 
 
 
Table 3-Overview of Tyrosine inhibitors as Therapeutic Targets [46]. 
 Imatinib Dasatinib Nilotinib Sunitinib Sorafenib Pazopanib Lapatinib 
Bcr-abl + + +     
c-kit + + + + + +  
PDGF-R + + + + + +  
EGF-R1    +   + 
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Associating these factors with an already selective (although indirect) methodology like 
nanoparticles may represent a step forward in cancer treatment. Not only will it reduce the side 
effects of the inhibitors but also guide the particles towards cells that are overexpressing the 
targeted proteins, which is the case of tumor cells [47], [49]. 
 
1.4.1 Varlitinib  
 
Varlitinib (Figure 4) is a selective and potent ErbB1 and ErbB2 inhibitor and functions as a 
reversible ATP-competitive inhibitor with nanomolar potency (Ki=1 nM) both in vitro and in cell-
based proliferation assays using A431 and BT-474 cells. It is an AKT pathway inhibitor in cells that 
contains active ErbB-2 receptors. It also suppresses ErbB-2 and ErbB-1 phosphorylation in human 
cancer cells, such as BT-474 and that overexpress ErbB-2 and ErbB-1, respectively. When dosed 
orally, ARRY-334543 inhibits growth of human tumor xenografts that overexpress ErbB-1 (A431) 
or ErbB-2 (MDA-MD-453) in a dose-dependent manner. This activity is superior to that seen with a 
benchmark compound [50]. Based on potency, selectivity and efficacy data, the compound is 
currently in development as an anti-cancer agent. 
 
 
 
 
 
 
 
 
Figure 6 - Varlitinib chemical structure [50] 
 
 
 
  
12 
 
 
 
 
  
13 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
  
14 
 
 
 
  
15 
 
 
 
2.1. Materials 
 
Doxorubicin and varlitinib were purchased from Selleck Chemicals LLC (USA). Sodium citrate, 
tetrachloroauric (III) acid (HAuCL4; 99.99% trace metal basis, 30 wt% in dilute HCl) and dimethyl 
sulfoxide (DMSO) were purchased from Sigma-Aldrich (Germany). Phosphate buffered saline (PBS: 
0.01 M, 0.0027 M KCl, 0.137 M NaCl, pH 7.4) was purchased from Sigma-Aldrich (Germany). α-
thiol-ω-carboxyl (polyethylene glycol) (molecular weight 394.57 Da) was purchased from 
Prochimia (Poland). Sulfo-NHS (N-hydroxysulfosuccinimide, molecular weight 217.3 Da) was 
purchased from Fluka (Germany). 1-ethyl-3-(3dimethylaminopropyl)-carbodiimide (EDC, 
molecular weight 191.7 Da) was purchased from Sigma-Aldrich (Germany). 
 
2.2. System 
 
2.2.1. Pegylated gold nanoparticle synthesis 
 
Gold Nanoparticles (AuNPs) were synthesized by reduction of HAuCl4 using sodium citrate, a 
process based on the Turkevich-Frens method [29] [30]. HAuCl4 aqueous solution was heated to 
its boiling point and stirred. Trisodium citrate was swiftly added and boiled during 12 minutes. 
Finally, the solution was allowed to cool off for posterior functionalization. Pegylation of AuNPs 
(PEGAuNPs) was achieved through addition of α-thiol-ω-carboxyl polyethylene glycol (PEG) 
capped with carboxylate group at a molar ratio of 1:1000. The mixture was stirred at room 
temperature for approximately 1 hour. The final solution was centrifuged at 13400 rpm during 10 
minutes and the pellet was ressuspended in water, to remove the unbound PEG molecules. The 
concentration of the PEGAuNPs was determined by the Lambert-Beer Law assuming the molar 
absorptivity of the particles plasmon resonance band at 526 nm being 2.33 x 108 M-1 cm-1 [51]. 
 
2.2.2. Conjugation of Doxorubicin to PEGAuNPs 
 
Doxorubicin stock solution was prepared in DMSO at room temperature [1mM], and dilutions 
were performed by addition of water to obtain the desired concentrations. EDC and S-NHS were 
used as reagents to functionalize the PEG layer in the AuNPs, thus increasing its reactivity 
towards the drug. To conjugate doxorubicin to the gold nanoparticles, firstly, EDC was added to 
6 ml of PEGAuNPs solution and stirred at room temperature. Secondly, S-NHS was added but with 
a reaction time of 5 minutes. After, 1 mL of doxorubicin in solution was added, with an 
estimated reaction time of 4 hours, at room temperature and constant stirring. The ratios for the 
reaction were: EDC and S-NHS at 1:4 molar ratio and 1:1 of doxorubicin, both regarding PEG. To 
remove the unbound drug, and estimate the conjugation efficiency of the process, the resulting 
solution was centrifuged at 13000 rpms during 10 minutes and most of the supernatant was 
discarded and replaced with water. 
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2.2.2. Conjugation of Varlitinib to PEGAuNPs 
 
Varlitinib stock solution was prepared in DMSO at room temperature [1,5mM], and dilutions 
were performed by addition of water to obtain the desired concentrations. EDC and S-NHS were 
used as reagents to functionalize the PEG layer in the AuNPs, increasing its reactivity towards 
the drug. To conjugate varlitinb to the gold nanoparticles, firstly, EDC was added to 6 ml of 
PEGAuNPs solution and stirred at room temperature and, secondly, S-NHS was added. Finally, 1 
mL of varlitinb in solution was added, with an estimated reaction time of 4 hours, at room 
temperature and constant stirring. The ratios for the reaction were: EDC and S-NHS at 1:4 molar 
ratio and 1:1 of varlitinb, both regarding PEG. To remove the unbound drug, and estimate the 
conjugation efficiency of the process, the resulting solution was centrifuged at 13000 rpms 
during 10 minutes and most of the supernatant was discarded and replaced with water. 
 
2.3. Methods 
 
2.3.1. Dynamic Light Scattering (DLS) 
 
Dynamic Light Scattering is a method used to determine the size of particles in a solution and 
their size distribution in dispersion. It measures the intensity of the dispersed light by a molecule 
or particle through time. Temperature and viscosity of the sample must be known as these 
factors will disturb or alter the dynamic behavior of the particles, leading to misinterpretations 
of their size. This method is also vital to infer any alteration in the particle’s surface, since any 
change will affect its diffusion speed [52]. 
The incident light from the laser will be scattered by any particles in the solution.  If the 
particles are static, the amount of scattered light will remain constant. But, if they are in 
constant motion, as it’s the case of nanoparticles in suspension (Brownian movements), the light 
intensity will vary. By measuring the variations of light intensity through time, DLS provides 
information on average particle size and size distribution in suspension. The rate of change of 
scattered light is directly proportional to the movement of the particles and can be related to 
their diffusion coefficient. Then, NPs size can be calculated from the diffusion coefficient, using 
Stokes-Einstein equation: 
    
  
     
  
where Rh is Laser hydrodynamic radius of the scattering particle; Ds is the translational 
diffusion coefficient, which depends on the size of the particle, on the surface structure and on 
the concentration and type of ions in solution; k is the Boltzmann’s constant; T is the absolute 
temperature and η is the viscosity [53]. 
The hydrodynamic diameter of the particles in suspension was analyzed by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK), at a constant 
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temperature of 25ºC. Size measurements were performed at a scattering angle of 173º in a 12 
mm2 polystyrene cuvette (Sarstedt, Germany). 
 
2.3.2. Zeta potential 
 
Electrophoretic light scattering (ELS), also known as Laser Doppler Microelectrophoresis, is 
used to infer the zeta potential (ζ –potential), a fundamental parameter that describes the 
electrostatic interactions between particles in a dispersion and its stability. Particles in a 
suspension attract ions to their surface. These ions form an electrical double layer covering the 
particle surface. This double layer consists of an inner layer, the Stern layer where counterions 
are strongly adsorbed, and an outer layer, where ions diffuse more freely. This diffuse layer 
defines the boundary of the particle as a single charged unit and the electric potential that 
exists at this boundary is called the zeta potential. Particles with very positive or very negative ζ 
–potential will repel each other and avoid aggregation. On the other hand, low absolute zeta 
potential values results in aggregation and flocculation. A physically stable nanosuspension will 
have a minimum zeta potential of absolute value of 30 mV [54]. 
Electrophoresis is an electrokinetic effect based on the movement of the particles when 
submitted to an electric field. Forces related to the particles viscosity will tend to oppose such 
movement, and when equilibrium is reached between these two opposing forces, the particles 
move with constant velocity. The velocity will depend on several factors: viscosity (η), zeta 
potential, the dielectric constant (ε) and the electrophoretic mobility (µE). Henry’s Law 
correlates the zeta potential and the electrophoretic mobility [55]: 
   
          
  
 
where μ is the eletrophoretic mobility; ε, the dielectric constant of the dispersant; ζ, the 
zeta potential; f(ka), is the Henry function and η, the viscosity coefficient. 
 Identically to the Dynamic Scattering Light, the ZetaSizer Nano ZS was the instrument used 
to obtain measurements of zeta potencial by ELS. Folded capillary cells from Malvern 
(Worcestershire, UK) were used and the dispersant medium was water. Mean values for each 
preparation were obtained by triplicate measurements.  
 
2.3.3. Absorption Spectroscopy 
 
To estimate the concentration of gold nanoparticles in solution from UV absorvance (A) at 
around 526 nm, calculations using the Lambert-Beer law were performed: 
        
 where l is the distance through the sample; C is the concentration of the absorbing species 
and ε is a constant known as the molar absorptivity, which is a molecular property in a given 
solvent at a specific temperature and pressure. 
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Spectrums of PEGAuNPs and DOXPEGAuNPs were obtained by UV-Vis absorption using a 1 cm 
quartz cuvette, at room temperature by a Shimadzu UV-1700 PharmaSpec spectrophotometer. 
 
2.3.4. Fourier Transform Infrared Spectroscopy (FTIR) 
 
Infrared Spectroscopy is a technique that provides information regarding the chemical 
composition of a material through the identification of its functional groups. It uses low energy 
radiation, to avoid sample damage, by emission of its electrons [56]. Each functional group 
vibrates after absorbing a specific wavelength, which frequency corresponds to specific 
molecular energy levels. By analyzing the sample reflectance and transmittance on the infrared 
region at different frequencies, a FTIR spectrum is outlined [57]. 
The AuNPs, PEGAuNPs, DOXPEGAuNPs and VarlitinibPEGAuNPs solutions were analyzed by 
Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR). The samples 
were centrifuged during 15 minutes at 14500 rpms, in order to obtain a dense pellet to minimize 
water-associated interference in the readings. ATR-FTIR spectra were recorded with an ALPHA 
FTIR Spectrometer (Bruker) in the spectral range 4000-400 cm-1, resolution of 4 cm-1 and 40 
scans, at room temperature. 
 
2.3.5. Fluorescence 
 
Fluorimetry consists of a technique used in the study, both quantitatively and qualitatively, 
of substances through a fluorescent phenomenon, resulting from the absorption of radiant energy 
and posterior emission of a portion of such energy. The major advantages of this technique are 
its superior sensitivity when compared with UV-vis spectroscopy (about 100 times more sensitive) 
and higher selectivity, since not all substances that absolve electromagnetic radiation are 
capable of emitting fluorescence. The latter may also be regarded as a limitation to the method, 
restringing the array of substances that can be studied [58], [59]. 
Both conjugated nanosystems used in this work, with doxorubicin and varlitinib, were 
quantified through fluorescence measures. Conjugation efficiency, compound stability and in 
vitro release studies all rely on this methodology to achieve viable results. The excitation and 
emission wavelengths were as followed: for doxorubicin, λex=485 nm and λem= 520 nm; and for 
Varlitinib λex=360 nm and λem= 485 nm. Fluorescence measures of AuNPs and PEGAuNPs were also 
performed for these wavelengths, as negative control.  
 
2.3.5.1. Stability studies 
 
As previously mentioned, fluorescence measurements are considered a viable manner to 
verify the stability or structural integrity of several compounds. Solutions with a known 
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concentration (approximately 8µM) of both doxorubicin and varlitinib were prepared at room 
temperature and kept at 37 ºC during 72 hours. Fluorescence readings were carried out at 
several timepoints during this period, to verify the stability of the anticancer drugs at body 
temperature. 
 
 
2.3.5.2. in vitro Drug release studies 
 
In vitro drug release studies of doxorubicin and varlitinib conjugated PEGAuNPs were carried 
out at 37 ºC by dialysis using a regenerated cellulose membrane (molecular weight cut off, 
MWCO: 8 kDa, purchased from Spectrum Labs Europe BV, Netherlands). Initial conjugated-
PEGAuNPs concentration was of approximately 8 nM, and the solutions were incubated in 4 mL of 
PBS 0.01 M, with constant magnetic stirring. 
The drug concentrations in the dialysate buffer were analyzed through time using 
fluorimetric analysis at the λex=485 nm and λem= 520 nm for doxorubicin and λex=360 nm and λem= 
485 nm for varlitinib. 
 
2.3.6. Transmission Electron Microscopy 
 
Transmission electron microscopy (TEM) is arguably the most efficient and versatile 
technique to characterize the morphology of nanomaterials. This technique has a much higher 
resolution when compared with other microscopic tools, such as light microscopy and is based on 
the interaction of an electron beam with the sample through which it passes. When the beam 
contacts with the sample, electrons will interact with it, and part of them may be transmitted 
through the sample. These transmitted electrons are captured and focused onto a phosphor 
screen at the bottom of the microscope where the image is outlined. The beam that reaches the 
phosphor screen consisted of different amounts of electrons that pass through particular regions 
of the sample and this difference is what causes the image contrast. Darker areas of the image 
represent the regions of the sample through which fewer electrons were transmitted, due to the 
greater thickness or density. On the other hand, brighter areas are the result of increased 
electronic transmission through the sample, representing thin regions of the sample [60], [61].  
The morphological examination of the NPs was performed by TEM Yeol Yem 1400 at an 
accelerating voltage of 80kV (Tokyo, Japan). For that purpose, the samples were prepared with 
negative staining. 5 μL samples were stained with 2% (v/v) uranyl acetate for 45 seconds, 
immobilized on copper grids (Formvar/Carbon on 400 mesh Cu (50) from Agar Scientific), and air-
dried for TEM visualization. TEM samples must be prepared in order to improve their 
visualization. Uranyl acetate is a heavy metal salt capable of scattering electrons, leading to an 
enhancement in the image contrast [62]. 
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3.1. Gold Nanoparticles Characterization 
 
Gold Nanoparticles (AuNPs) were synthesized by reduction of HAuCl4 using sodium 
citrate, a process based on the Turkevich-Frens method and posteriorly functionalized with PEG 
[29]. The size distribution and zeta potential of the PEGAuNPs was determined by Dynamic light 
scattering (DLS) and Laser Doppler velocimetry (LDV), respectively. The influence of the 
pegylation was evaluated through the analysis of physicochemical properties of the produced 
AuNPs and PEGAuNPs with the results being presented in table 4 (n=8). 
 Table 4-Zeta potential and mean hydrodynamic diameter values for both AuNPs and PEGAuNPs. 
 Hydrodynamic diameter (nm) Zeta Potential (mV) 
AuNPs 18±6  -37±9 
PEGAuNPs 22±7   -41±7  
 
The results in table 4 clearly indicate a slight increase in the hydrodynamic diameter and 
zeta potential through PEG-functionalization. The particles size increased due to the covalent 
attachment of PEG polymer chains, which translates in a lower affinity towards other particles in 
suspension leading to an increasingly negative zeta potential value, conferring stability to 
colloidal suspension. 
The particles in suspension were also be evaluated through TEM, as shown in Figures 7-A 
and 7-B. 
 
Figure 7-TEM analysis of: a) AuNPs; b) PEGAuNPs. Scale bar is 0.5 µm. 
TEM analysis of both AuNPs and PEGAuNPs show the nanoparticles in spherical shape and 
a size range of approximately 20nm that is in agreement with DLS measurements.  It is also 
possible to observe the low degree of aggregation of the nanoparticles in suspension.  
Furthermore, FTIR analysis was carried through to evaluate the chemical structure of 
both AuNPs and PEGAuNPs, and to confirm that pegylation of the particles was indeed achieved 
(Figure 8). 
A B 
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Figure 8-FTIR spectra of gold nanoparticles (AuNPs), pegylated gold nanoparticles (PEGAuNPs) and PEG in 
solution. 
Figure 8 shows the FTIR spectra of AuNPs, synthesized PEGAuNPs, and pure PEG in 
solution. In contrast to the spectrum of bare AuNPs, IR transmittance peak is present in the 
spectrum of PEGAuNPs, and this peak is assigned as follows: 2,850–3,000 cm−1(–CH2 stretching, 
highlighted) [28]. 
 
3.2. Gold Nanoparticles stability 
 
According to Aryal et al., acidic pH influences the behavior and stability of gold 
nanoparticles [2]. To determine the influence of this factor in the stability of the NPs, 
continuous studies at 37ºC in 0.01M PBS buffers with distinct pH values were performed. The 
results are described in tables 5, 6 and 7.  
 
Table 5 - Zeta potential and Hydrodynamic diameter values for PEGAuNPs in DI water, over a period of 
42 days. Hydrodynamic diameter results are presented as mean ± SD (% of total population). 
H2O (pH=7,0) Hydrodynamic diameter (nm) Zeta Potential (mV) 
Before dilution 22 ± 7 -41 ± 7 
0 days 35 ± 6 -39 ± 7 
1 day 36 ± 6 -37 ± 6 
7 days 32±6 -42 ± 7 
14 days 
34 ± 6 (59,0%) 
318 ± 103 (41,0%) 
-38 ± 7 
28 days 
44 ±7 (77,3%) 
312 ± 92 (22,7%) 
-36 ± 6 
42 days 
65 ±12(97,8%) 
498 ± 266 (2,2%) 
-36 ± 6 
350850135018502350285033503850
AuNPs PEGAuNPs PEG
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Table 6-Zeta potential and mean diameter values for PEGAuNPs at pH 7.4, over a period of 42 days. 
Hydrodynamic diameter results are presented as mean ± SD (% of total population). 
pH = 7.4 Hydrodynamic diameter (nm) Zeta Potential (mV) 
Before dilution 22 ± 7 -41 ± 7 
0 days 21 ± 5 -27 ± 5 
1 day 
24 ± 6 (80 %) 
462 ± 104 (20%) 
-27 ± 5 
7 days 23 ± 6 (100%) -29 ± 5 
14 days 
22 ± 6 (50,1%) 
411 ± 102 (49,9%) 
-30 ± 6 
28 days 
21 ± 6 (62,1%) 
452 ± 121  (37,9%) 
-29 ± 5 
42 days 
20  ± 6 (70,5%) 
708 ± 204 (29,5%) 
-27 ± 5 
 
 
Table 7-Zeta potential and mean diameter values for PEGAuNPs at pH 5.3 over a period of 42 days, in 
pH=5.3 PBS buffer solution. Hydrodynamic diameter results are presented as mean ± SD (% of total 
population). 
pH= 5.3 Hydrodynamic diameter (nm) Zeta Potential (mV) 
Before dilution 22 ± 7 -41 ± 7 
0 days 
187 ± 47 (84,9%) 
21 ± 6 (15,1%) 
-26 ± 4 
1 day 
21 ± 6 (74,2 %) 
378 ± 96 (25,8%) 
-26 ± 3 
7 days 
25 ± 6 (66%) 
378 ± 100 (34 %) 
-25 ± 4 
14 days 
420 ± 107 (62,8%) 
28 ± 6 (37,2%) 
-25 ± 4 
28 days 
24 ± 6 (52,3%) 
512 ± 126 (47,7%) 
-26 ± 3 
42 days 
18 ± 5 (59,1%) 
701 ± 272 (40,9%) 
-24 ± 4 
 
Analyzing the zeta potential values, it is clear that an acidic pH value destabilize the 
system at a quicker rate, which is an indicator for drug delivery since the particles are 
internalized through lysosomes, where the pH is quite lower than the biological value of 7.4 [63]. 
It is also observable that the particles tend to aggregate with time at pH 7.4 and 5.3. An effect 
clearly more prone to happen in acidic pH, as the hydrodynamic diameter data sustains. Studies 
at pH=3 were also preformed but, due to the immediate nanoparticle aggregation, the 
continuous study of the solution could not be performed. 
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3.3. Conjugation of PEGAuNPs with antitumor agents and in 
vitro Release Studies 
 
In this work, two antitumor of distinct purpose were selected: doxorubicin, a widely used 
chemotherapy agent and varlitinib, a specific target towards overexpressed receptors in several 
tumor cell lines. 
The methodology used for both NPs preparation was similar. Firstly, a drug calibration 
curve was obtained through fluorescence readings (data not shown), to facilitate drug 
quantification in both conjugation efficiency and release studies. Drug stability in 0.01M PBS 
solution at 37ºC was also assessed. These assays allow the determination of the activity of the 
drug with time. The stability assays of conjugated PEGAuNPs were performed at 37 ºC and in 
vitro release experiment were investigated. All assays were performed in triplicate. 
  
3.3.1. Conjugation of PEGAuNPs with Doxorubicin: Dox-
PEGAuNPs 
 
A solution of doxorubicin [8µM] was quantified through fluorescence readings, with 
λex=485 nm and λem= 520 nm. The drug stability assay is presented in Figure 9. 
 
Figure 9 - Doxorubicin stability assay, at 37ºC in PBS. 
By analyzing the fluorescence levels of doxorubicin in solution, it is clear that the 
fluorimetric profile of the drug is stable through time, an indicator of structural integrity of the 
compound [58]. 
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The conjugation efficiency was determined by fluorimetric analysis of the supernatant of 
conjugate preparation. The analysis protocol is strictly similar to the one used in the studies 
regarding doxorubicin. The results for conjugation efficiency and physicochemical analysis are 
represented in Table 8.  
Table 8 - Physico -chemical characterization of-PEGAuNPs and Dox-PEGAuNP 
 
Hydrodynamic diameter 
(nm) 
Zeta Potential 
(mV) 
Conjugation 
efficiency (%) 
Relative [Dox] , µM 
PEGAuNPs 22±7 (100%) -41±7 - - 
Dox-PEGAuNPs 
206±78 (74,6%) 
29±10 (22,8%) 
-37±6 50±5 ≈3,6 
 
According to table 8, it is possible to observe that there is a small, but not significant, 
decrease in the zeta potential values. The hydrodynamic diameter of the PEGAuNPs changed 
from 22±7 nm to 29±10 nm. These results indicate some level of interaction between the Dox 
molecules and the surface of the PEGAuNPs. The conjugation efficiency value was obtained by 
fluorescence readings the supernatant and it is 50±5%. Therefore, the final concentration of Dox 
conjugated with PEGAuNPs is determined to be of 3.6 µM. 
Additionally, FTIR analysis was performed to evaluate the functionalization of PEGAuNPs 
with doxorubicin. For reference purposes, analysis of Doxorubicin as a powder was done. 
 
Figure 10-FTIR spectra of: A) Doxorubicin powder; B) Pegylated gold nanoparticles (PEGAuNPs) and 
Doxorubicin conjugated gold nanoparticles (DoxPegAuNPs). 
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Figure 10A represents pure doxorubicin, and bands at 1620 cm-1, 1734 cm-1 and 2917 cm-1 
were attributed to N-H  bending, C=O stretching vibration and C–H stretching, respectively [45]. 
Most importantly, for pure DOX, the characteristic band at 3430 cm-1 was due to N-H stretching 
vibrations for primary amine structure [64]. 
By analyzing Figure 9 B, it is visible that in the case of DOXPEGAuNPs, the amine peak of 
pure DOX at 3430 cm-1 was broadened and a new amide peak at 1050 cm-1 appears. They are 
indicators of a covalent bonding between protonated amine groups of the doxorubicin molecule 
with the surface of PEGAuNPs, resulting in the formation of an amide [45], [65], [66]. 
According to FTIR analysis, it could be suggested that DOX molecules were successfully 
attached to PEGAuNPs surfaces, and that -NH2 group of DOX is the active site for the attachment 
to the PEGAuNPs. 
To determine the stability of the conjugate in near biological conditions, a 37 ºC in PBS 
study was performed. The hydrodynamic diameter and zeta potential were analyzed to access 
particle stability. Results are presented in Table 9.  
 
Table 9-Physico-chemical characterization of DOXPEGAuNPs over a period of 72 hours, at 37ºC. 
Dox-PEGAuNPs Hydrodynamic diameter (nm) 
Zeta Potential 
(mV) 
0 hours 
206 ± 78 (74.6%) 
28 ± 10 (25.4%) 
-37 ± 6 
12 hours 
201 ± 74 (71,5%) 
25 ± 10 (29.5%) 
-34 ±6 
24 hours 
159 ± 47 (71.8%) 
26 ± 10 (28.2%) 
-34 ± 6 
36 hours 
215 ± 68 (74.7%) 
24 ± 8 (25.3%) 
-33 ± 5 
48 hours 
145 ± 56 (71.5%) 
25 ± 9 (28.5%) 
-32 ± 5 
72 hours 
144 ± 42 (63.3%) 
28 ± 12 (32.8%) 
-31 ± 6 
 
According to the values depicted in table 9, a small decrease in the zeta potential values 
is verified. Although it is not enough to consider the particles as unstable in solution since they 
remain below the -30 mV, a standard value for particle stability [4]. Analyzing the data regarding 
the nanoparticle’s hydrodynamic diameter, it is visible that there is a tendency towards 
aggregation through time. 
To investigate the DOX release conjugated with PEGAuNPs, in vitro release experiments 
of DOXPEGAuNPs and DOX alone were performed using dialysis membranes (MWCO 8kD) in PBS 
0.01 M  at 37 ºC. The concentration of DOXPEGAuNPs used was of approximately 10nM (with a 
relative [DOX]=3.6 µM) and 7.2 µM for DOX solution. The results are shown in Figure 10. 
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Figure 11-Release profile for Doxorrubicin conjugated PEG-AuNPs 
 
It is observed in Figure 11 a significant gap in Dox release profile in presence of 
PEGAuNPs when compared to Dox alone. At 24 hours, the amount of Dox released was of 62% and 
34% for Dox alone and in combination with PEGAuNPs, respectively. These results suggest some 
level of interaction between the drug and the surface of PEGAuNPs. After 60 hours, it is visible 
an arrest in the release of Dox, both in the presence and absence of PEGAuNPs. 
 
 
 
 
3.3.2. Varlitinib-PEGAuNPs 
 
Varlitinib in solution was quantified through fluorescence readings with λex=360 nm and 
λem= 485 nm. The conjugation efficiency was determined by fluorimetric analysis of the 
supernatant of conjugate preparation. The analysis protocol is strictly similar to the one used in 
the studies regarding doxorubicin. The results for conjugation efficiency and physicochemical 
analysis are represented in Table 10.  
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Table 10-Physico-chemical characterization of both PEGAuNPs and Varlitinib-PEGAuNPs, conjugation 
efficiency and relative drug concentration in the conjugate solution. 
 
Hydrodynamic diameter 
(nm) 
Zeta Potential 
(mV) 
Conjugation 
efficiency (%) 
Relative [Varlitinib]  
µM 
PEGAuNPs 22±7 (100%) -41±7 - - 
Varlitinib-PEGAuNPs 
30±11 (56.2%) 
240±101 (43.8%) 
-27±8  95±3 ≈7 
 
The values presented in table 10 sustain the argument that an interaction occurs 
between varlitinib and the PEGAuNPs, due to the decrease in zeta potential of the particles. The 
percentage of conjugated drug with PEGAuNPs is 95±3%. This value indicates an adsorption 
towards the particles surface, since it is almost undetectable the presence of Varlitinib in the 
supernatant after the conjugation reaction with PEGAuNPs. 
Additionally, FTIR analysis was performed to evaluate the functionalization of PEGAuNPs 
with Varlitinib. For reference purposes, analysis of Varlitinib as a powder was done. 
 
Figure 12-FTIR spectra of: A)Varlitinib powder; B) Pegylated gold nanoparticles (PEGAuNPs) and 
Varlitinib conjugated gold nanoparticles (Varlitinib-PEGAuNPs). 
Figure 12-A represents the FTIR spectra of Varlitinib powder, in which several 
characteristic peaks are observed. Some of these peaks are concordant to the spectra for 
VarlitinbPEGAuNPs, and are highlighted in the both spectra. These results clearly indicate the 
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association of the inhibitor to the nanoparticles, as concluded by comparison of the FTIR 
spectra of PEGAuNPs and VarlitinibPEGAuNPS (Figure 12-B), sustained by the data acquired 
through analysis of the drug powder. The characteristic imine peak at 1660 cm-1 appears in 
the FTIR spectra for VarlitinibPEGAuNPs (highlighted in Figure 12-B) , indicating the covalent 
bond between the secondary amide present in the Varlitinib molecule and the carboxylic 
group at the end of the PEG chain [36], [66–69]. According to the literature, it is expected to 
observe an amine characteristic peak at 1100-1000 cm-1 which is highlighted in Figure 12-B. 
This peak is an indicator of the presence of the drug conjugated with the NPs [36].  
To determine the stability of the conjugate in conditions approaching the ones in a 
biological environment, a 37ºC in PBS study was performed. The indicators of particle stability 
were the hydrodynamic diameter and zeta potential. Results are presented in Table 11.  
 
Table 11-Physico-chemical characterization of Varlitinib-PEGAuNPs over a period of 72 hours, at 37ºC. 
Varlitinib-PEGAuNPs Hydrodynamic diameter (nm) Zeta Potential (mV) 
0 hours 
30 ± 11 (56.2%) 
240 ± 101 (43.8%) 
-27 ± 8 
12 hours 
200 ± 82 (52.5%) 
27 ± 10 (47.5%) 
-24 ± 6 
24 hours 
29 ±11 (55.9%) 
243 ± 107 (44.1%) 
-24 ± 6 
36 hours 
25 ± 10 (56.2%) 
177 ± 72 (43.8%) 
-23 ± 5 
48 hours 
205 ± 92 (56.7%) 
28 ± 10 (43.3%) 
-21 ± 5 
72 hours 
27 ± 11 (59.7%) 
142 ± 67 (40.3%) 
-17 ± 4 
 
According to the values in table 11, the significant decrease in the zeta potential values 
show instability in the system after 72 hours of incubation. These values may be a result of a 
good conjugation efficiency of Varlitinib with PEGAuNPs. 
 
Finally, the in vitro drug-release studies were performed at 37ºC in PBS, to evaluate the 
controlled release of the conjugated therapeutic agent in conditions approaching a biological 
system. The in vitro release profile of the nanocarrier is demonstrated in Figure 13. 
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Figure 13-In vitro Release profile for Varlitinib conjugated PEG-AuNPs 
Although the values for drug released cannot be determined prior to 24 hours, it is easily 
observable in Figure 13 a delay in the release of Varlitinib when conjugated with PEGAuNPs. At 
24 hour the Varlitinib release is 22% and 11% for Varlitinib alone and conjugated with the 
PEGAuNPs, respectively. Therefore, it is clear that an interaction occurs between the drug and 
the nanoparticles, through covalent binding. 
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Conclusions and Future Perspectives 
 
 
 
This thesis reports the design and characterization of nanocarriers – pegylated gold 
nanoparticles – conjugated with anticancer drugs to be used as drug delivery systems in cancer 
therapies. 
According to the results obtained, a good pegylation of gold nanoparticles was achieved, 
increasing its stability in suspension for a long period of time. It was proved that particles are pH 
sensitive, which may be a surplus when regarding cellular studies. 
It can also be shown that, for conjugation studies, both systems present good 
conjugation efficiency, especially for varlitinib, through covalent binding with the PEG chains at 
the nanoparticles surface. Additionally, in vitro release results show a controlled release of both 
antitumoral drugs when conjugated with the gold nanoparticles. These conjugated nanoparticles 
are also relatively stable for a short period of time at near-biological conditions, defining them 
as suitable for some assays regarding its cellular impact or therapeutic efficacy. 
For future work, it is planned to access the stability of the nanoparticles in Fetal Bovine 
Serum (FBS), in order to mimic the biological environment. Moreover, cytotoxicity assays must 
be performed, to evaluate the toxicity of both PEGAuNPs and its respective conjugates towards 
cancer cell lines and normal cell lines. These assays will also allow the determination of the 
optimal concentration of nanoparticles at which they are biocompatible. Posteriorly, the 
internalization of the nanoparticles within the cells will be verified by laser scanning confocal 
microscopy. It is expected that the nanoparticles are localized in the cytoplasm with higher 
concentration in the perinuclear region, as observed in previous works of the group. 
  
34 
 
 
 
 
 
   
35 
 
 
 
 
 
References 
 
 
 
[1] D. M. Parkin, P. Pisani, and J. Ferlay, “Global cancer statistics,” CA Cancer J Clin, vol. 
49, no. 2, pp. 1,33–64, 2011. 
[2] J. D. Byrne, T. Betancourt, and L. Brannon-Peppas, “Active targeting schemes for 
nanoparticle systems in cancer therapeutics,” Adv. Drug Deliv. Rev., vol. 60, no. 15, 
pp. 1615–1626, 2008. 
[3] J. You, R. Zhang, C. Xiong, M. Zhong, M. Melancon, S. Gupta, A. M. Nick, A. K. Sood, 
and C. Li, “Effective photothermal chemotherapy using doxorubicin-loaded gold 
nanospheres that target EphB4 receptors in tumors,” Cancer Res., vol. 72, no. 18, pp. 
4777–4786, 2012. 
[4] Y. J. Gu, J. Cheng, C. W. Y. Man, W. T. Wong, and S. H. Cheng, “Gold-doxorubicin 
nanoconjugates for overcoming multidrug resistance,” Nanomedicine Nanotechnology, 
Biol. Med., vol. 8, no. 2, pp. 204–211, 2012. 
[5] B. Asadishad, M. Vossoughi, and I. Alemzadeh, “Folate-receptor-targeted delivery of 
doxorubicin using polyethylene glycol-functionalized gold nanoparticles,” Ind. Eng. 
Chem. Res., vol. 49, no. 4, pp. 1958–1963, 2010. 
[6] E. Boisselier and D. Astruc, “Gold nanoparticles in nanomedicine: preparations, 
imaging, diagnostics, therapies and toxicity.,” Chem. Soc. Rev., vol. 38, no. 6, pp. 
1759–1782, 2009. 
[7] S. Gill, R. Löbenberg, T. Ku, S. Azarmi, W. Roa, and E. J. Prenner, “Nanoparticles: 
Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A 
Review,” J. Biomed. Nanotechnol., vol. 3, no. 2, pp. 107–119, Jun. 2007. 
[8] L. Dykman and N. Khlebtsov, “Gold nanoparticles in biomedical applications: recent 
advances and perspectives,” Chem. Soc. Rev., vol. 41, no. 6, p. 2256, 2012. 
[9] V. P. Torchilin, “Multifunctional nanocarriers.,” Adv. Drug Deliv. Rev., vol. 58, no. 14, 
pp. 1532–55, Dec. 2006. 
[10] M. C. Daniel and D. Astruc, “Gold Nanoparticles: Assembly, Supramolecular Chemistry, 
Quantum-Size-Related Properties, and Applications Toward Biology, Catalysis, and 
Nanotechnology,” Chem. Rev., vol. 104, no. 1, pp. 293–346, 2004. 
36 
 
 
 
[11] W. Cai, T. Gao, H. Hong, and J. Sun, “Applications of gold nanoparticles in cancer 
nanotechnology.,” Nanotechnol. Sci. Appl., vol. 2008, no. 1, pp. 17–32, 2008. 
[12] R. Esfand and D. a. Tomalia, “Poly(amidoamine) (PAMAM) dendrimers: From 
biomimicry to drug delivery and biomedical applications,” Drug Discov. Today, vol. 6, 
no. 8, pp. 427–436, 2001. 
[13] M. R. Papasani, G. Wang, and R. a. Hill, “Gold nanoparticles: The importance of 
physiological principles to devise strategies for targeted drug delivery,” Nanomedicine 
Nanotechnology, Biol. Med., vol. 8, no. 6, pp. 804–814, 2012. 
[14] W. H. De Jong and P. J. a Borm, “Drug delivery and nanoparticles:applications and 
hazards.,” Int. J. Nanomedicine, vol. 3, no. 2, pp. 133–149, 2008. 
[15] P. Ghosh, G. Han, M. De, C. K. Kim, and V. M. Rotello, “Gold nanoparticles in delivery 
applications,” Adv. Drug Deliv. Rev., vol. 60, no. 11, pp. 1307–1315, 2008. 
[16] A. Kumari, S. K. Yadav, and S. C. Yadav, “Biodegradable polymeric nanoparticles 
based drug delivery systems,” Colloids Surfaces B Biointerfaces, vol. 75, no. 1, pp. 1–
18, 2010. 
[17] Z. Liu, Y. Jiao, Y. Wang, C. Zhou, and Z. Zhang, “Polysaccharides-based nanoparticles 
as drug delivery systems,” Adv. Drug Deliv. Rev., vol. 60, no. 15, pp. 1650–1662, 2008. 
[18] P. Ramos-Cabrer and F. Campos, “Liposomes and nanotechnology in drug 
development: focus on neurological targets.,” Int. J. Nanomedicine, vol. 8, pp. 951–
60, Jan. 2013. 
[19] S. Vemuri and C. T. Rhodes, “Preparation and characterization of liposomes as 
therapeutic delivery systems: A review,” Pharm. Acta Helv., vol. 70, no. 2, pp. 95–
111, 1995. 
[20] B. Maherani, E. Arab-Tehrany, M. R. Mozafari, C. Gaiani, and M. Linder, “Liposomes: A 
Review of Manufacturing Techniques and Targeting Strategies,” Curr. Nanosci., vol. 7, 
no. 3, pp. 436–452, 2011. 
[21] S. Aryal, J. J. Grailer, S. Pilla, D. a. Steeber, and S. Gong, “Doxorubicin conjugated 
gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers,” 
J. Mater. Chem., vol. 19, no. 42, p. 7879, 2009. 
[22] I. Brigger, C. Dubernet, and P. Couvreur, “Nanoparticles in cancer therapy and 
diagnosis,” Adv. Drug Deliv. Rev., vol. 54, no. 5, pp. 631–651, 2002. 
[23] M. R. Mozafari, C. Johnson, S. Hatziantoniou, and C. Demetzos, “Nanoliposomes and 
their applications in food nanotechnology.,” J. Liposome Res., vol. 18, no. 4, pp. 309–
27, Jan. 2008. 
[24] N. Ribeiro, S. R. Sousa, C. a van Blitterswijk, L. Moroni, and F. J. Monteiro, “A 
biocomposite of collagen nanofibers and nanohydroxyapatite for bone regeneration.,” 
Biofabrication, vol. 6, no. 3, p. 035015, Jun. 2014. 
[25] H. Maeda, G. Y. Bharate, and J. Daruwalla, “Polymeric drugs for efficient tumor-
targeted drug delivery based on EPR-effect,” Eur. J. Pharm. Biopharm., vol. 71, no. 3, 
pp. 409–419, 2009. 
37 
 
 
 
[26] J. Fang, H. Nakamura, and H. Maeda, “The EPR effect : Unique features of tumor 
blood vessels for drug delivery , factors involved , and limitations and augmentation of 
the effect,” Adv. Drug Deliv. Rev., vol. 63, no. 3, pp. 136–151, 2011. 
[27] D. Xiaowei and J. M. Russell, “Nanomedicinal strategies to treat multidrug-resistant 
tumors: Current Progress,” Nanomedicine, vol. 5, no. 4, pp. 597–615, 2011. 
[28] S. K. Seol, D. Kim, S. Jung, W. S. Chang, and J. T. Kim, “One-step synthesis of PEG-
coated gold nanoparticles by rapid microwave heating,” J. Nanomater., vol. 2013, 
2013. 
[29] J. Kimling, M. Maier, V. Okenve, V. Kotaidis, H. Ballot, a Plech, and B. Okenve, 
“Turkevitch method for gold nanoparticle synthesis revisited,” J. Phys. Chem. B, vol. 
110, no. 95 mL, pp. 15700–15707, 2006. 
[30] M. Brust, M. Walker, D. Bethell, D. J. Schiffrin, and R. Whyman, “Synthesis of Thiol-
derivatised Gold Nanoparticles in,” J. Chem. Soc., pp. 801–802, 2000. 
[31] S. S. Agasti, S. Rana, M. H. Park, C. K. Kim, C. C. You, and V. M. Rotello, 
“Nanoparticles for detection and diagnosis,” Adv. Drug Deliv. Rev., vol. 62, no. 3, pp. 
316–328, 2010. 
[32] S. A. Kumar, S. A. Kumar, Y.-A. Peter, Y.-A. Peter, J. L. Nadeau, and J. L. Nadeau, 
“Facile biosynthesis, separation and conjugation of gold nanoparticles to doxorubicin,” 
Nanotechnology, vol. 19, no. 49, p. 495101, 2008. 
[33] J. Gao, X. Huang, H. Liu, F. Zan, and J. Ren, “Colloidal stability of gold nanoparticles 
modified with thiol compounds: bioconjugation and application in cancer cell 
imaging.,” Langmuir, vol. 28, no. 9, pp. 4464–71, 2012. 
[34] R. Bhattacharya, C. R. Patra, R. Verma, S. Kumar, P. R. Greipp, and P. Mukherjee, 
“Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells,” Adv. Mater., 
vol. 19, no. 5, pp. 711–716, 2007. 
[35] S. C. Coelho, G. Almeida, M. C. Pereira, F. Santos-Silva, M. A.N., and Coelho, 
“Functionalized Gold Nanoparticles improve Afatinib delivery into Cancer cells,” 2012. 
[36] S. C. Coelho, S. Rocha, M. C. Pereira, P. Juzenas, and M. A. N. Coelho, “Enhancing 
Proteasome-Inhibitor Effect by Functionalized Gold Nanoparticles,” J. Biomed. 
Nanotechnol., vol. 9, no. xx, pp. 1–7, 2013. 
[37] H. G. Keizer, H. M. Pinedo, G. J. Schuurhuis, and H. Joenje, “Doxorubicin 
(adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.,” 
Pharmacol. Ther., vol. 47, no. 2, pp. 219–231, 1990. 
[38] S. Chalasani, K. V. Prakash, R. P. Pulla, R. Tekula, and B. Umasankar, “Development 
and Validation of Doxorubicin Hcl in Spectrophotometry,” vol. 3, no. 3, pp. 216–218, 
2013. 
[39] S. Granados-Principal, J. L. Quiles, C. L. Ramirez-Tortosa, P. Sanchez-Rovira, and Mc. 
Ramirez-Tortosa, “New advances in molecular mechanisms and the prevention of 
adriamycin toxicity by antioxidant nutrients,” Food Chem. Toxicol., vol. 48, no. 6, pp. 
1425–1438, 2010. 
[40] A. de Luca, N. Moroni, A. Serafino, A. Primavera, A. Pastore, J. Z. Pedersen, R. 
Petruzzelli, M. G. Farrace, P. Pierimarchi, G. Moroni, G. Federici, P. Sinibaldi 
Vallebona, and M. Lo Bello, “Treatment of doxorubicin-resistant MCF7/Dx cells with 
38 
 
 
 
nitric oxide causes histone glutathionylation and reversal of drug resistance,” 
Biochem. J., vol. 440, no. 2, pp. 175–183, 2011. 
[41] M. Zimmermann, A. S. Arachchige-Don, M. S. Donaldson, R. F. Dallapiazza, C. E. 
Cowan, and M. C. Horne, “Elevated cyclin G2 expression intersects with DNA damage 
checkpoint signaling and is required for a potent G2/M checkpoint arrest response to 
doxorubicin,” J. Biol. Chem., vol. 287, no. 27, pp. 22838–22853, 2012. 
[42] G. Mandili, A. Khadjavi, V. Gallo, V. G. Minero, L. Bessone, F. Carta, G. Giribaldi, and 
F. Turrini, “Characterization of the protein ubiquitination response induced by 
Doxorubicin,” FEBS J., vol. 279, no. 12, pp. 2182–2191, 2012. 
[43] W. Sun, A. L. Kalen, B. J. Smith, J. J. Cullen, and L. W. Oberley, “Enhancing the 
antitumor activity of adriamycin and ionizing radiation,” Cancer Res., vol. 69, no. 10, 
pp. 4294–4300, 2009. 
[44] J. Spadavecchia, R. Perumal, A. Barras, J. Lyskawa, P. Woisel, W. Laure, C.-M. 
Pradier, R. Boukherroub, and S. Szunerits, “Amplified plasmonic detection of DNA 
hybridization using doxorubicin-capped gold particles.,” Analyst, vol. 139, no. 1, pp. 
157–164, 2014. 
[45] N. S. Elbialy, M. M. Fathy, and W. M. Khalil, “Doxorubicin loaded magnetic gold 
nanoparticles for in vivo targeted drug delivery,” Int. J. Pharm., vol. 490, no. 1–2, pp. 
190–199, 2015. 
[46] J. T. Hartmann, M. Haap, H.-G. Kopp, and H.-P. Lipp, “Tyrosine kinase inhibitors - a 
review on pharmacology, metabolism and side effects.,” Curr. Drug Metab., vol. 10, 
no. 5, pp. 470–481, 2009. 
[47] A. Arora and E. Scholar, “Role of tyrosine kinase inhibitors in cancer therapy,” J. 
Pharmacol. Exp. …, vol. 315, no. 3, pp. 971–979, 2005. 
[48] E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei, “Cellular pharmacology of 
gemcitabine,” Ann. Oncol., vol. 17, no. SUPPL. 5, pp. 7–12, 2006. 
[49] H. W. Kao, Y. Y. Lin, C. C. Chen, K. H. Chi, D. C. Tien, C. C. Hsia, M. H. Lin, and H. E. 
Wang, “Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic 
agent in a tumor animal model,” Bioorganic Med. Chem. Lett., vol. 23, no. 11, pp. 
3180–3185, 2013. 
[50] G. Miknis, “ARRY-334543, a Potent, Orally Active, Small Molecule Inhibitor of EGFR and 
ErbB-2,” Array BioPharma Inc., 2007. 
[51] P. Baptista, G. Doria, D. Henriques, E. Pereira, and R. Franco, “Colorimetric detection 
of eukaryotic gene expression with DNA-derivatized gold nanoparticles,” J. 
Biotechnol., vol. 119, no. 2, pp. 111–117, 2005. 
[52] J. Holoubek, “Some applications of light scattering in materials science,” J. Quant. 
Spectrosc. Radiat. Transf., vol. 106, no. 1–3, pp. 104–21, 1995. 
[53] W. I. I. Goldburg, “Dynamic light scattering,” Am. J. Phys., vol. 67, no. 12, pp. 1152–
1160, 1999. 
[54] J. M. Freire, M. M. Domingues, J. Matos, M. N. Melo, A. S. Veiga, N. C. Santos, and M. 
a R. B. Castanho, “Using zeta-potential measurements to quantify peptide partition to 
lipid membranes,” Eur. Biophys. J., vol. 40, no. 4, pp. 481–487, 2011. 
39 
 
 
 
[55] M. Kaszuba, J. Corbett, F. M. Watson, and A. Jones, “High-concentration zeta 
potential measurements using light-scattering techniques.,” Philos. Trans. A. Math. 
Phys. Eng. Sci., vol. 368, no. 1927, pp. 4439–4451, 2010. 
[56] H. Silva, Espectroscopia no infravermelho por transformada de Fourier (FTIR). 
Fundamentos e aplicação na caracterização de materiais de construção. Lisbon: LNEC, 
2007. 
[57] P. R. Griffiths, Fourier Transform Infrared Spectrometry. Wiley-Interscience, 2007. 
[58] J. R. Lakowicz, “Principles of Fluorescence Spectroscopy,” Princ. Fluoresc. Spectrosc., 
pp. 1–23, 2006. 
[59] X. Dai, Z. Yue, M. E. Eccleston, J. Swartling, N. K. H. Slater, and C. F. Kaminski, 
“Fluorescence intensity and lifetime imaging of free and micellar-encapsulated 
doxorubicin in living cells,” Nanomedicine Nanotechnology, Biol. Med., vol. 4, no. 1, 
pp. 49–56, 2008. 
[60] L. Reimer and H. Kohl, Transmission Electron Microscopy. NY, USA, 2008. 
[61] D. B. Williams and C. B. Carter, “Transmission electron microscopy: A textbook for 
materials science,” Transm. Electron Microsc. A Textb. Mater. Sci., no. September 
2015, pp. 1–760, 2009. 
[62] R. H. . Haschemeyer, “Negative Staining,” Princ. Tech. Electron Microsc. - Biol. Appl., 
1972. 
[63] G. C. Baltazar, S. Guha, W. Lu, J. Lim, K. Boesze-Battaglia, A. M. Laties, P. Tyagi, U. 
B. Kompella, and C. H. Mitchell, “Acidic Nanoparticles Are Trafficked to Lysosomes 
and Restore an Acidic Lysosomal pH and Degradative Function to Compromised ARPE-
19 Cells,” PLoS One, vol. 7, no. 12, pp. 1–10, 2012. 
[64] S. Rana, a. Gallo, R. S. Srivastava, and R. D. K. Misra, “On the suitability of 
nanocrystalline ferrites as a magnetic carrier for drug delivery: Functionalization, 
conjugation and drug release kinetics,” Acta Biomater., vol. 3, no. 2, pp. 233–242, 
2007. 
[65] A. Z. Mirza and H. Shamshad, “Preparation and characterization of doxorubicin 
functionalized gold nanoparticles,” Eur. J. Med. Chem., vol. 46, no. 5, pp. 1857–1860, 
May 2011. 
[66] W. Gallagher, “Infrared Spectroscopy : Theory,” J. Mol. Spectrosc., vol. 214, no. 1, 
pp. 155–164, 2002. 
[67] S. Pine, Organic Chemistry. 1987. 
[68] S. C. Coelho, S. Rocha, P. Juzenas, P. Sampaio, G. M. Almeida, F. S. Silva, M. C. 
Pereira, and M. a N. Coelho, “Gold nanoparticle delivery-enhanced proteasome 
inhibitor effect in adenocarcinoma cells.,” Expert Opin. Drug Deliv., pp. 1–8, 2013. 
[69] S. C. Coelho, S. Rocha, P. Sampaio, M. C. Pereira, and M. a. N. Coelho, “Encapsulation 
of a proteasome inhibitor with gold-polysaccharide nanocarriers,” J. Nanoparticle 
Res., vol. 16, no. 4, p. 2368, 2014.  
 
